Matches in SemOpenAlex for { <https://semopenalex.org/work/W2918261004> ?p ?o ?g. }
- W2918261004 endingPage "e14504" @default.
- W2918261004 startingPage "e14504" @default.
- W2918261004 abstract "Abstract Introduction: Interventional ablation has been demonstrated to represent an effective therapy in patients with atrial fibrillation (AF), leading to restoration and maintenance of sinus rhythm in the majority of cases. However, recurrence of AF is encountered in 35% to 40% of cases, and the causes for this frequent complication have not been elucidated so far. Material and methods: Here we present the study protocol of the FIBRO-RISK trial, a prospective, single-center, cohort study which aims to investigate the impact of inflammatory-mediated myocardial fibrosis on the risk of recurrence after successful catheter ablation of atrial fibrillation. The level of systemic inflammation in the pre-ablation and immediate post-ablation period will be assessed on the basis of serum levels of inflammatory biomarkers (hsCRP, matrix metalloproteases, interleukin-6), while the level of cardiac fibrosis will be determined based on cardiac magnetic resonance imaging associated with complex post-processing techniques for mapping myocardial fibrosis at the level of left atrium and left ventricle. At the same time, the amount of epicardial fat will serve as an indirect marker of localized inflammation and will be determined at different levels in the heart (surrounding left atrium, right atrium or the entire heart), while ventricular function will be assessed on the basis of serum levels of NT-proBNP prior to the procedure. All these parameters will be investigated in patients with successful ablation of AF, who will be divided into 2 groups: group 1 – patients who develop AF recurrence at 1-year, and group 2 – patients with no recurrence of AF at 1-year. In all patients, the following biomarkers will be determined: serum levels of inflammatory biomarkers and NT-proBNP at 24 hours and 1-year post procedure, the amount of myocardial fibrosis at the level of left atrium and left ventricle at baseline +/− 7 days, and the amount of epicardial fat surrounding left atrium, right atrium and the entire heart at baseline +/− 7 days. The primary endpoint of the study will be represented by the rate of AF recurrence at 1-year post ablation, documented by either ECG or Holter monitoring. The secondary endpoints of the study will consist in: In conclusion, FIBRO-RISK will be the first CMR-based study that will investigate the impact of inflammation-mediated myocardial fibrosis and ventricular remodeling on the risk of recurrence after successful ablation of AF, aiming to validate inflammatory biomarkers and myocardial fibrosis as predictors for AF recurrence." @default.
- W2918261004 created "2019-03-11" @default.
- W2918261004 creator A5012322815 @default.
- W2918261004 creator A5012408693 @default.
- W2918261004 creator A5031553438 @default.
- W2918261004 creator A5038960837 @default.
- W2918261004 creator A5043482576 @default.
- W2918261004 creator A5043549672 @default.
- W2918261004 creator A5048136690 @default.
- W2918261004 creator A5085226794 @default.
- W2918261004 creator A5088418144 @default.
- W2918261004 date "2019-03-01" @default.
- W2918261004 modified "2023-10-18" @default.
- W2918261004 title "Impact of inflammation-mediated myocardial fibrosis on the risk of recurrence after successful ablation of atrial fibrillation – the FIBRO-RISK study" @default.
- W2918261004 cites W101847764 @default.
- W2918261004 cites W1225851237 @default.
- W2918261004 cites W19468421 @default.
- W2918261004 cites W1970242617 @default.
- W2918261004 cites W1976598631 @default.
- W2918261004 cites W1989115657 @default.
- W2918261004 cites W2009877148 @default.
- W2918261004 cites W2023546790 @default.
- W2918261004 cites W2057769601 @default.
- W2918261004 cites W2074270616 @default.
- W2918261004 cites W2089940123 @default.
- W2918261004 cites W2097289752 @default.
- W2918261004 cites W2105894476 @default.
- W2918261004 cites W2107714800 @default.
- W2918261004 cites W2111379709 @default.
- W2918261004 cites W2120386224 @default.
- W2918261004 cites W2120795994 @default.
- W2918261004 cites W2139245232 @default.
- W2918261004 cites W2140997835 @default.
- W2918261004 cites W2146673314 @default.
- W2918261004 cites W2156011709 @default.
- W2918261004 cites W2165762489 @default.
- W2918261004 cites W2167423131 @default.
- W2918261004 cites W2242693401 @default.
- W2918261004 cites W2323676296 @default.
- W2918261004 cites W2747865904 @default.
- W2918261004 cites W4234891227 @default.
- W2918261004 doi "https://doi.org/10.1097/md.0000000000014504" @default.
- W2918261004 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6831404" @default.
- W2918261004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30817568" @default.
- W2918261004 hasPublicationYear "2019" @default.
- W2918261004 type Work @default.
- W2918261004 sameAs 2918261004 @default.
- W2918261004 citedByCount "9" @default.
- W2918261004 countsByYear W29182610042020 @default.
- W2918261004 countsByYear W29182610042021 @default.
- W2918261004 countsByYear W29182610042022 @default.
- W2918261004 countsByYear W29182610042023 @default.
- W2918261004 crossrefType "journal-article" @default.
- W2918261004 hasAuthorship W2918261004A5012322815 @default.
- W2918261004 hasAuthorship W2918261004A5012408693 @default.
- W2918261004 hasAuthorship W2918261004A5031553438 @default.
- W2918261004 hasAuthorship W2918261004A5038960837 @default.
- W2918261004 hasAuthorship W2918261004A5043482576 @default.
- W2918261004 hasAuthorship W2918261004A5043549672 @default.
- W2918261004 hasAuthorship W2918261004A5048136690 @default.
- W2918261004 hasAuthorship W2918261004A5085226794 @default.
- W2918261004 hasAuthorship W2918261004A5088418144 @default.
- W2918261004 hasBestOaLocation W29182610041 @default.
- W2918261004 hasConcept C126322002 @default.
- W2918261004 hasConcept C164705383 @default.
- W2918261004 hasConcept C188816634 @default.
- W2918261004 hasConcept C2775914520 @default.
- W2918261004 hasConcept C2776131983 @default.
- W2918261004 hasConcept C2776914184 @default.
- W2918261004 hasConcept C2778902805 @default.
- W2918261004 hasConcept C2778921608 @default.
- W2918261004 hasConcept C2779161974 @default.
- W2918261004 hasConcept C2780559512 @default.
- W2918261004 hasConcept C3018763269 @default.
- W2918261004 hasConcept C71924100 @default.
- W2918261004 hasConceptScore W2918261004C126322002 @default.
- W2918261004 hasConceptScore W2918261004C164705383 @default.
- W2918261004 hasConceptScore W2918261004C188816634 @default.
- W2918261004 hasConceptScore W2918261004C2775914520 @default.
- W2918261004 hasConceptScore W2918261004C2776131983 @default.
- W2918261004 hasConceptScore W2918261004C2776914184 @default.
- W2918261004 hasConceptScore W2918261004C2778902805 @default.
- W2918261004 hasConceptScore W2918261004C2778921608 @default.
- W2918261004 hasConceptScore W2918261004C2779161974 @default.
- W2918261004 hasConceptScore W2918261004C2780559512 @default.
- W2918261004 hasConceptScore W2918261004C3018763269 @default.
- W2918261004 hasConceptScore W2918261004C71924100 @default.
- W2918261004 hasIssue "9" @default.
- W2918261004 hasLocation W29182610041 @default.
- W2918261004 hasLocation W29182610042 @default.
- W2918261004 hasLocation W29182610043 @default.
- W2918261004 hasLocation W29182610044 @default.
- W2918261004 hasOpenAccess W2918261004 @default.
- W2918261004 hasPrimaryLocation W29182610041 @default.
- W2918261004 hasRelatedWork W2086897532 @default.
- W2918261004 hasRelatedWork W2143427407 @default.
- W2918261004 hasRelatedWork W2179224909 @default.
- W2918261004 hasRelatedWork W2384340384 @default.